Immunoglobulin constant region Fc receptor binding agents
AssigneesGliknik Inc., University of Maryland, Baltimore
InventorsScott E. Strome, Dan H. Schulze, David S. Block, Henrik Olsen
Life of this patent
Estimating the term…
Abstract
IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacements compound's efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization. Finally, the replacement compounds are used to treat a wide range of diseases, including inflammatory and autoimmune diseases.
Claims12
A core stradomer comprising a core moiety linked to at least two homodimeric core stradomer units,
- wherein each of the at least two homodimeric core stradomer units comprises at least one IgG Fc domain,
- wherein each of the at least one IgG Fc domains is capable of binding a human low affinity Fcγ receptor (FcγR) selected from FcγRIIA, FcγRIIB, FcγRIIIA, and FcγRIIIB, and
- wherein the core stradomer specifically binds to at least two human low affinity FcγRs through the at least two homodimeric core stradomer units, and
- wherein the at least two homodimeric core stradomer units do not comprise either an antigen binding domain or a non-immunoglobulin protein.
Dependencies are inferred from the claim text.